Theocharis Panaretakis

List of Publications by Year
in descending order

47 papers	17,664 citations	147566 31 h-index	214527 47 g-index
49 all docs	49 docs citations	49 times ranked	32880 citing authors

#	Article	IF	Citations
1	Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene, 2022, 41, 757-769.	2.6	12
2	ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment. Cancers, 2022, 14, 2939.	1.7	2
3	Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. Cancer Research, 2022, 82, 3158-3171.	0.4	9
4	Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clinical Cancer Research, 2021, 27, 3253-3264.	3.2	26
5	Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. IScience, 2021, 24, 102388.	1.9	12
6	Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene, 2021, 40, 4592-4603.	2.6	10
7	A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-NaÃ¯ve Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 990-999.	3.2	11
8	Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers, 2020, 12, 244.	1.7	21
9	Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab). European Journal of Cancer, 2018, 97, 33-40.	1.3	10
10	Caspase-2 associates with FAN through direct interaction and overlapping functionality. Biochemical and Biophysical Research Communications, 2018, 499, 822-828.	1.0	1
11	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
12	A novel community driven software for functional enrichment analysis of extracellular vesicles data. Journal of Extracellular Vesicles, 2017, 6, 1321455.	5.5	314
13	Caspase-3â€“dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells. Blood, 2016, 128, 2655-2665.	0.6	36
14	Energyâ€requiring uptake of prostasomes and PC3 cellâ€derived exosomes into nonâ€malignant and malignant cells. Journal of Extracellular Vesicles, 2016, 5, 29877.	5.5	45
15	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
16	Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. Oncotarget, 2016, 7, 74966-74978.	0.8	61
17	Malignant cellâ€derived extracellular vesicles express different chromogranin epitopes compared to prostasomes. Prostate, 2015, 75, 1063-1073.	1.2	6
18	Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget, 2015, 6, 21740-21754.	0.8	109

#	Article	IF	Citations
19	Sorafenib-induced defective autophagy promotes cell death by necroptosis. Oncotarget, 2015, 6, 37066-37082.	0.8	53
20	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	2.1	686
21	Multitargeted therapies for multiple myeloma. Autophagy, 2013, 9, 255-257.	4.3	5
22	Effect of Acute Exercise on Prostate Cancer Cell Growth. PLoS ONE, 2013, 8, e67579.	1.1	82
23	Cisplatin-induced apoptosis and development of resistance are transcriptionally distinct processes. Cell Cycle, 2012, 11, 3723-3723.	1.3	2
24	Sorafenib Has Potent Antitumor Activity against Multiple Myeloma <i>In Vitro</i>, <i>Ex Vivo</i>, and <i>In Vivo</i> in the 5T33MM Mouse Model. Cancer Research, 2012, 72, 5348-5362.	0.4	44
25	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
26	Tumor cell-derived exosomes: A message in a bottle. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 103-111.	3.3	226
27	Autophagy: cancer therapyâ€™s friend or foe?. Future Medicinal Chemistry, 2010, 2, 285-297.	1.1	31
28	Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death. Cell Cycle, 2010, 9, 3144-3149.	1.3	25
29	Viral subversion of immunogenic cell death. Cell Cycle, 2009, 8, 860-869.	1.3	60
30	Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation. Free Radical Biology and Medicine, 2009, 46, 1607-1613.	1.3	12
31	Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO Journal, 2009, 28, 578-590.	3.5	683
32	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1Î²â€"dependent adaptive immunity against tumors. Nature Medicine, 2009, 15, 1170-1178.	15.2	1,614
33	Immunogenic cancer cell death: a key-lock paradigm. Current Opinion in Immunology, 2008, 20, 504-511.	2.4	271
34	Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2â€deoxyglucose and etomoxir. International Journal of Cancer, 2008, 123, 476-483.	2.3	77
35	Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone. Cancer Research, 2008, 68, 5301-5308.	0.4	101
36	Interferon Î± Induces Nucleus-independent Apoptosis by Activating Extracellular Signal-regulated Kinase 1/2 and c-Jun NH₂-Terminal Kinase Downstream of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin. Molecular Biology of the Cell, 2008, 19, 41-50.	0.9	53

#	Article	IF	Citations
37	Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica, 2007, 92, 1460-1469.	1.7	55
38	Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from â€œSilentâ€• to Immunogenic. Cancer Research, 2007, 67, 7941-7944.	0.4	134
39	Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. International Journal of Cancer, 2007, 120, 175-180.	2.3	187
40	Ectoâ€calreticulin in immunogenic chemotherapy. Immunological Reviews, 2007, 220, 22-34.	2.8	183
41	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. Journal of Molecular Medicine, 2007, 85, 1069-1076.	1.7	68
42	Two distinct steps of Bak regulation during apoptotic stress signaling: Different roles of MEKK1 and JNK1. Experimental Cell Research, 2006, 312, 1581-1589.	1.2	9
43	Alternative Signaling Pathways Regulating Type I Interferon-Induced Apoptosis. Journal of Interferon and Cytokine Research, 2005, 25, 799-810.	0.5	41
44	Doxorubicin Requires the Sequential Activation of Caspase-2, Protein Kinase CÎ´, and c-Jun NH2-terminal Kinase to Induce Apoptosis. Molecular Biology of the Cell, 2005, 16, 3821-3831.	0.9	98
45	Interferon Î±-induced Apoptosis in Tumor Cells Is Mediated through the Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Signaling Pathway. Journal of Biological Chemistry, 2004, 279, 24152-24162.	1.6	106
46	Interferon-Î±-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene, 2003, 22, 4543-4556.	2.6	72
47	Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to Doxorubicin. Journal of Biological Chemistry, 2002, 277, 44317-44326.	1.6	137